Boston Scientific, J&J Analyses Aim To Convince CMS To Raise DES Payments
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific and J&J are providing additional external data analyses to counter CMS' claim that more evidence is required to justify altering the drug-eluting stent diagnosis-related groups (DRGs)
You may also be interested in...
Medicare DES Rates Sustained; CMS Cites Paltry Data To Back DRG Change
CMS will reconsider proposals to restructure the drug-eluting stent DRGs in 11 months after more data become available to support industry and physician assertions of significant cost differences between complex and non-complex cases
Medicare DES Rates Sustained; CMS Cites Paltry Data To Back DRG Change
CMS will reconsider proposals to restructure the drug-eluting stent DRGs in 11 months after more data become available to support industry and physician assertions of significant cost differences between complex and non-complex cases
“Appropriate” Defibrillator, Drug-Eluting Stent Payments Pondered By CMS
CMS is seeking comments on ways to structure inpatient payment for implantable cardiac defibrillators so that clinicians will consider using less sophisticated devices in clinically appropriate situations